Apyx Medical Inc (APYX)vsBoston Scientific Corp (BSX)
APYX
Apyx Medical Inc
$4.47
+4.20%
HEALTHCARE · Cap: $165.82M
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 36774% more annual revenue ($20.61B vs $55.90M). BSX leads profitability with a 17.3% profit margin vs -16.4%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
APYX
Hold39
out of 100
Grade: F
BSX
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+30.5%
Fair Value
$5.64
Current Price
$4.47
$1.17 discount
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.5% year-over-year
Growing faster than its price suggests
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Areas to Watch
Trading at 14.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : APYX
The strongest argument for APYX centers on Revenue Growth, PEG Ratio. Revenue growth of 32.5% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : APYX
The primary concerns for APYX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.08 is elevated, increasing financial risk.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Key Dynamics to Monitor
APYX profiles as a hypergrowth stock while BSX is a mature play — different risk/reward profiles.
APYX carries more volatility with a beta of 1.35 — expect wider price swings.
APYX is growing revenue faster at 32.5% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 39/100), backed by strong 17.3% margins and 11.6% revenue growth. APYX offers better value entry with a 30.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apyx Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?